Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01210222 · ClinicalTrials.gov registry record · Phase 2
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01210222 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 35 participants.
The verdict
NCT01210222, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well trebananib works in treating patients with persistent or recurrent endometrial cancer. Trebananib may stop the growth of endometrial cancer by blocking blood flow to the tumor.
Interventions
- BIOLOGICAL Trebananib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-06-06 |
| Est. Completion | 2016-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01210222
The ClinicalTrials.gov registry entry for NCT01210222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trebananib is the first listed.
NCT01210222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01210222 about?
NCT01210222 is a clinical study titled "Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer". This phase II trial studies the side effects and how well trebananib works in treating patients with persistent or recurrent endometrial cancer. Trebananib may stop the growth of endometrial cancer by blocking blood flow to the tumor.
What is the current status of trial NCT01210222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2011-06-06. Estimated completion is 2016-07-16.
What interventions are being tested in trial NCT01210222?
The interventions under investigation include: Trebananib (BIOLOGICAL).
Who is sponsoring clinical trial NCT01210222?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.